Abstract
The increase of fungal infectious diseases and lack of safe and efficacious antifungal drugs result in the urgent need of new therapeutic strategies. Here, we repurposed the lovastatin (LOV) as a synergistic antifungal potentiator to itraconazole (ITZ) against Candida albicans planktonic cells and biofilms in vitro for the first time. Mutants from ergosterol biosynthesis pathway were employed and key gene expression profiles of ergosterol pathway were also measured. LOV single treatment was unable to inhibit C. albicans strains except the ERG3 and ERG11 double mutant. LOV and ITZ combination was capable of inhibiting the C. albicans planktonic cells and biofilms synergistically including the ITZ resistant mutants. The synergistic antifungal ability was stronger in either ERG11 or ERG3 dysfunctional mutants compared to wild type. The combination lost the synergistic activities in the ERG11 and ERG3 double mutant, while it was sensitive to LOV single treatment. The expression of HMG1, encoding HMG-CoA the target of LOV, was significantly upregulated in ERG11 and ERG3 double mutant strain by the treatment of the combination at 1.5 and 3 h. The combination also significantly increased the HMG1 expression in mutants from ergosterol pathway compared with wild type. The ERG11 and ERG3 gene expressions were upregulated by ITZ and its combination with LOV, but seemingly not by LOV single treatment after 1.5 and 3 h. The combination of LOV and ITZ on C. albicans planktonic cells and biofilms highlights its potential clinical practice especially against the azole drug-resistant mutants.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aftab BT, Dobromilskaya I, Liu JO, Rudin CM (2011) Itraconazole inhibits angiogenesis and tumor growth in non–small cell lung cancer. Cancer Res 71(21):6764–6772
Akins RA (2005) An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol 43(4):285–318
Anderson JB (2005) Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Rev Microbiol 3(7):547–556
Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A, Monk BC (2009) Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 22(2):291–321. https://doi.org/10.1128/CMR.00051-08
Carole AS, Gerald RD (1994) Infections in bone marrow transplant recipients. Clin Infect Dis 18(3):273–281
Chen X, Ren B, Chen M, Liu M-X, Ren W, Wang Q-X, Zhang L-X, Yan G-Y (2014) ASDCD: antifungal synergistic drug combination database. PLoS One 9(1):e86499
Chen X, Ren B, Chen M, Wang Q, Zhang L, Yan G (2016) NLLSS: predicting synergistic drug combinations based on semi-supervised learning. PLoS Comput Biol 12(7):e1004975
Coste A, Selmecki A, Forche A, Diogo D, Bougnoux ME, d'Enfert C, Berman J, Sanglard D (2007) Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot Cell 6(10):1889–1904. https://doi.org/10.1128/ec.00151-07
Coste A, Turner V, Ischer F, Morschhauser J, Forche A, Selmecki A, Berman J, Bille J, Sanglard D (2006) A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172(4):2139–2156. https://doi.org/10.1534/genetics.105.054767
Crowley JH, Parks LW (1999) Dual physiological effects of antifungal sterol biosynthetic inhibitors on enzyme targets and on transcriptional regulation. Pest Manag Sci 55(4):393–397
Cuervo G, Garcia-Vidal C, Nucci M, Puchades F, Fernández-Ruiz M, Mykietiuk A, Manzur A, Gudiol C, Pemán J, Viasus D (2013) Effect of statin use on outcomes of adults with candidemia. PLoS One 8(10):e77317
Enoch DA, Ludlam HA, Brown NM (2006) Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 55(7):809–818. https://doi.org/10.1099/jmm.0.46548-0
Fonzi WA, Irwin MY (1993) Isogenic strain construction and gene mapping in Candida albicans. Genetics 134(3):717–728
Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292(5519):1160–1164
Liu Z, Myers LC (2017) Mediator tail module is required for Tac1-activated CDR1 expression and azole resistance in Candida albicans. Antimicrob Agents Chemother 61(11):e01342–e01317. https://doi.org/10.1128/aac.01342-17
Loeffler J, Stevens DA (2003) Antifungal drug resistance. Clin Infect Dis 36(Suppl 1):S31–S41. https://doi.org/10.1086/344658
Lorenz R, Parks L (1990) Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob Agents Chemother 34(9):1660–1665
Macreadie IG, Johnson G, Schlosser T, Macreadie PI (2006) Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 262(1):9–13
Martin MV (2000) The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review. J Antimicrob Chemother 45(4):555
Mathé L, Van Dijck P (2013) Recent insights into Candida albicans biofilm resistance mechanisms. Curr Genet 59(4):251–264
Menezes EA, AAd VJ, Silva CLF, Plutarco FX, Cunha MCS, Cunha FA (2012) In vitro synergism of simvastatin and fluconazole against Candida species. Rev Inst Med Trop São Paulo 54(4):197–199
Morschhauser J (2010) Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 47(2):94–106. https://doi.org/10.1016/j.fgb.2009.08.002
Nash JD, Burgess DS, Talbert RL (2002) Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol 51(2):105–109
Nobile CJ, Johnson AD (2015) Candida albicans biofilms and human disease. Annu Rev Microbiol 69:71–92
Nyilasi I, Kocsubé S, Krizsán K, Galgóczy L, Pesti M, Papp T, Vágvölgyi C (2010) In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol Lett 307(2):175–184
Odds FC (2003) Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 52(1):1–1
Odds FC, Brown AJP, Gow NAR (2003) Antifungal agents: mechanisms of action. Trends Microbiol 11(6):272–279. https://doi.org/10.1016/S0966-842X(03)00117-3
Perchellet JP, Perchellet EM, Crow KR, Buszek KR, Brown N, Ellappan S, Gao G, Luo D, Minatoya M, Lushington GH (2009) Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins. Int J Mol Med 24(5):633–643
Pfaller MA (2012) Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 125(1 Suppl):S3–S13. https://doi.org/10.1016/j.amjmed.2011.11.001
Qiao J, Kontoyiannis DP, Wan Z, Li R, Liu W (2007) Antifungal activity of statins against Aspergillus species. Med Mycol 45(7):589–593
Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, Kauffman CA (1994) Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 97(4):339–346. https://doi.org/10.1016/0002-9343(94)90300-X
Sanglard D, Coste A, Ferrari S (2009) Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res 9(7):1029–1050. https://doi.org/10.1111/j.1567-1364.2009.00578.x
Sanglard D, Ischer F, Parkinson T, Falconer D, Bille J (2003) Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 47(8):2404–2412
Shapiro RS, Robbins N, Cowen LE (2011) Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Bio Rev 75(2):213–267. https://doi.org/10.1128/mmbr.00045-10
Song JL, Lyons CN, Holleman S, Oliver BG, White TC (2003) Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. Med Mycol 41(5):417–425
Sun J, Qi C, Lafleur MD, Qi Q-g (2009) Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China. Int J Oral Sci 1(3):156–162
Xie JL, O'Meara TR, Polvi EJ, Robbins N, Cowen LE (2017) Staurosporine induces filamentation in the human fungal pathogen Candida albicans via signaling through Cyr1 and protein kinase A. mSphere 2(2):e00056. https://doi.org/10.1128/mSphere.00056-17
Xu Y, Chen L, Li C (2008) Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations. J Antimicrob Chemother 61(4):798–804. https://doi.org/10.1093/jac/dkn015
Zhang L, Yan K, Zhang Y, Huang R, Bian J, Zheng C, Sun H, Chen Z, Sun N, An R (2007) High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc Nati Acade Sci U S A 104(11):4606–4611
Acknowledgements
We greatly thank Prof. Dominique Sanglard for providing the C. albicans mutants. This work was supported by the National Natural Science Foundation of China (grant nos. 81600858, 81372889, and 81430011), National Key Research and Development Program of China (2016YFC1102700), and Youth Grant of the Science and Technology Department of Sichuan Province, China (2017JQ0028).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical statement
This article does not contain any studies with human participants or animals performed by any of the authors.
Electronic supplementary material
ESM 1
(PDF 207 kb)
Rights and permissions
About this article
Cite this article
Zhou, Y., Yang, H., Zhou, X. et al. Lovastatin synergizes with itraconazole against planktonic cells and biofilms of Candida albicans through the regulation on ergosterol biosynthesis pathway. Appl Microbiol Biotechnol 102, 5255–5264 (2018). https://doi.org/10.1007/s00253-018-8959-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-018-8959-8